Last reviewed · How we verify
Neovir (CRIDANIMOD)
Neovir (generic name: CRIDANIMOD) is a cridanimod drug. It is currently in Phase 3 development.
Neovir works by modulating the immune system to treat a specific condition.
Neovir, also known as Cridanimod, is a small molecule drug in the cridanimod class. Its original development is attributed to an unknown entity, and it is currently owned by an unspecified company. The target and indications for Neovir are not publicly disclosed, and its commercial status, including patent and generic availability, is unknown. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also not available. Further information on Neovir's safety profile and efficacy is required to fully understand its clinical utility.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CRIDANIMOD |
|---|---|
| Drug class | cridanimod |
| Target | Stimulator of interferon genes protein, Trypsin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Imagine your immune system is like a security guard that protects you from harm. Neovir helps the guard work more efficiently by fine-tuning its response to threats, reducing unnecessary inflammation and damage. This can help alleviate symptoms and improve outcomes for patients with certain conditions.
Approved indications
Common side effects
Key clinical trials
- Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza (PHASE3)
- An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer (PHASE2)
- Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neovir CI brief — competitive landscape report
- Neovir updates RSS · CI watch RSS
Frequently asked questions about Neovir
What is Neovir?
How does Neovir work?
What is the generic name of Neovir?
What drug class is Neovir in?
What development phase is Neovir in?
What does Neovir target?
Related
- Drug class: All cridanimod drugs
- Target: All drugs targeting Stimulator of interferon genes protein, Trypsin
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing